Fingolimod versus High Dose Interferon Beta-1a in Multiple Sclerosis: A Randomized Clinical Trial

Authors

  • Masoud Etemadifar Professor of Neurology, Department of neurology, Isfahan University of Medical Sciences, Isfahan, Iran
  • Pedram Moeini Resident of Neurology, Department of neurology, Isfahan University of Medical Sciences, Isfahan, Iran; [email protected]
  • Seyed-Masoud Nabavi Associate Professor of Neurology, Shahed University of Medical Sciences, Tehran, Iran
Abstract:

Background: High dose Interferon Beta and Fingolimod are efficient in Multiple Sclerosis. Objectives: Comparison the efficacy of these two drugs in patients with treatment failure on low dose interferon beta. Materials and Methods: The MS patients (McDonald criteria 2010) with the history of unbeneficial treatment on low dose interferon beta participated in this randomized clinical trial in MS clinic in a university hospital in Isfahan from 2014 to 2016. They were randomly assigned to two groups receiving high dose interferon beta-1a (Recigen) or Fingolimod. The number of relapses, EDSS, and Magnetic Resonance Imaging (MRI) findings were evaluated at the beginning, 3, 9, 12, and 18 months after intervention. The t-test and Mann Whitney U test and ANCOVA in SPSS version 20 were used. Results: A total of 120 MS patients with the mean age of 38.07±9.0 years included in this study and 35.8% of whom were males. The mean EDSS was lower in Fingolimod group from the 9th month to the end of intervention (1.80±1.05 vs. 2.17±0.95 in the 9th month and 1.95±0.92 vs. 2.30±0.96 in 18th month). The mean number of relapses was lower in Finglimod group significantly in the 12th and 18th months (0.91±0.76 vs. 1.27±0.77 in the 12th and 0.6±0.55 vs 1.0±0.71 in the 18th month). The mean values of new T2 lesions (1.00 vs. 1.47) and gadolinium enhancing lesions (0.467 vs. 0.817) were lower in Fingolimod group at the end of the study. Conclusion: Both treatments were beneficial with a significant superiority of Fingolimod. 

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Efficacy of interferon beta-1a in Iranian multiple sclerosis

Objective: To evaluate the clinical efficacy of onceweekly intramuscular interferon beta-1a (IFN B1a, Avonex Biogen) in Iranian multiple sclerosis (MS) patients. Methods: A 12 months, single blind clinical trial conducted from January 2001 to September 2003. Eighty patients with definite MS age 20 to 50 years were allocated to two groups. The first group received 30 microgram (6MIU) IFN B1a wee...

full text

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

BACKGROUND Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis. METHODS In this phase 2, randomized, blinded trial involving previously untreated, early, relapsing-remitting multiple sclerosis, we assigned 334 patients with scores of 3.0 or less on the Expanded Disability Status Scale and a dis...

full text

Meningioma growth during interferon beta-1A treatment for multiple sclerosis.

Fleury Diagnostic Center, Section of Radiology, São Paulo SP, Brazil; Santa Casa de Misericórdia de São Paulo, Section of Radiology, São Paulo SP Brazil; Santa Casa de Misericórdia de São Paulo, Section of Neurology, São Paulo SP, Brazil; Santa Casa de Misericórdia de São Paulo, Section of Neurosurgery, São Paulo SP, Brazil; Santa Casa de Misericórdia de São Paulo, Section of Pathology, São Pau...

full text

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

BACKGROUND Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an alpha4 integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies. METHODS We randomly assigned 1171 patients who, despite interferon beta-1a therapy, had had at leas...

full text

Early treatment with high-dose interferon beta-1a reverses cognitive and cortical plasticity deficits in multiple sclerosis.

Acute inflammation is associated with cognitive deficits and alterations of cortical plasticity in multiple sclerosis (MS). We tested whether early treatment with high-dose interferon (IFN) beta-1a, known to reduce inflammatory activity, improves cortical function and cognitive deficits in MS. Eighty treatment-naïve relapsing-remitting MS (RRMS)patients received IFN beta-1a (44 mcg) subcutaneously ...

full text

P 52: Interferon beta-a1 vs. Teriflunomide for Multiple Sclerosis

Multiple sclerosis (MS) is an inflammatory disorder, in which neurons in central nervous system (CNS) become demyelinated .MS is named for its formation of plaques due to sclerosis of myelin. Variable degree of demyelination results in mild, mediate or severe symptomatic episodes of this disease. It is commonly characterized by recurrent relapses and often followed by severe neurological disabi...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 3  issue 8

pages  1- 8

publication date 2017-02

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023